Almac Group extends personalised cancer vaccine production facilities
The Almac Group, a CDMO serving the pharmaceutical and biotech sectors globally, is expanding its Edinburgh Technopole facility to allow scale-up of its personalised cancer vaccine activities. Doubling its footprint in the Fleming Building to over 15,000 square feet, the company is investing in